Beltran Lab VideosProstate-Specific Membrane Antigen (PSMA) Dr. Beltran provided her insights on the use of PSMA as an imaging tool and therapeutic target in prostate cancer. She discussed our collaborative work with Drs. Scott Tagawa and Neil Bander at Weill Cornell Medicine supported by a Department of Defense Prostate Cancer Research Program Award! |
HPN328 - DLL3 T cell engager Dr. Beltran presented the interim ph1/2 results of HPN328 at 2024 GU ASCO showing HPN328 is well tolerated in patients with neuroendocrine tumors including neuroendocrine prostate cancer and clinically active. HPN328 is a T cell engager that recruits T cells to kill tumor cells that express DLL3, a unique tumor antigen. |
|
Neuroendocrine Prostate Cancer
Dr. Beltran shared her research at the DoD Prostate Cancer Research Program IMPACT meeting (2016). Genomic and epigenomic approaches to understand how and why some prostate cancer patients develop an aggressive neuroendocrine phenotype after therapy. |
NEPC Organoids We are using state-of-art technologies to develop three-dimension organoid model systems to investigate neuroendocrine prostate cancer progression. NEPC cells here express synaptophysin (green) protein, which is a classical neuroendocrine marker. Cellular nuclei are shown in blue. |
|
|
Organoid Growth We use advanced imaging tools to characterize tumor organoid growth and study how new treatments impact tumor cell phenotype and proliferation. |